The 2026 iCMLf Goldman Prize
Professor Meinolf Suttorp
The iCMLf is delighted to announce that Professor Meinolf Suttorp, a Senior Professor of Pediatric Hematology and Oncology from Dresden, Germany, is the recipient of the 2026 John Goldman Prize, in recognition of his outstanding and sustained contributions to the understanding and treatment of pediatric CML. The iCMLf John Goldman Prize recognises individuals whose work has significantly advanced the understanding and management of CML worldwide.
For decades, Professor Suttorp has been at the forefront of research and clinical care for children and adolescents with CML. Through his scientific leadership, international collaboration, and commitment to improving patient outcomes worldwide, he has helped establish the foundations of modern pediatric CML care.
A career dedicated to pediatric CML
Professor Suttorp has spent much of his academic career at the Children’s University Hospital Carl Gustav Carus in Dresden, where he served as Head of the Division of Pediatric Hematology and Oncology before becoming Senior Professor of Pediatric Hematology and Oncology at the Medical Faculty of the Technische Universität Dresden.
Over several decades, his work has shaped the clinical and scientific understanding of pediatric CML. Through academic clinical trials, international registries, and global collaborative networks, he has played a pivotal role in defining treatment strategies for children living with CML. His leadership in the CML-paed I and CML-paed II trials helped advance the optimisation of tyrosine kinase inhibitor therapy in pediatric patients, contributing to improved outcomes and new therapeutic approaches for this rare leukemia.
He studied organic chemistry at the University of Münster and thereafter human medicine at the University of Kiel in Germany, completing his medical training and doctoral work before specialising in pediatrics and pediatric hematology-oncology. Over the course of his career, he has authored or co-authored more than 250 scientific publications and has contributed to international guidelines and expert consensus statements on the management of pediatric CML.
"Professor Meinolf Suttorp has made transformative contributions to the field of chronic myeloid leukemia, particularly through his pioneering work in pediatric CML. His leadership in international collaborative trials, unwavering commitment to improving outcomes for children, and his strong dedication to patient advocacy have set new standards for care.
His work exemplifies the very spirit of the John Goldman Prize"
- Professor Andreas Hochhaus
Honoring a lifetime of advancing care for children with CML
Professor Suttorp’s work has helped clarify the biological and clinical differences between pediatric and adult CML, emphasising the need for dedicated research and child-specific treatment strategies. His research has addressed key clinical and biological questions in pediatric CML, including treatment optimisation, long-term toxicity, longitudinal growth and osseous development during therapy, and the possibility of treatment-free remission.
Throughout his career, Professor Suttorp has been a strong advocate for global collaboration. Because pediatric CML is extremely uncommon, international partnerships have been essential to advancing knowledge and improving care. Professor Suttorp has been instrumental in building and sustaining these collaborations, enabling clinicians and researchers around the world to collaborate in studying pediatric CML and developing evidence-based treatment approaches.
Contributions to the International CML Foundation
Professor Suttorp has been deeply involved in the work of the iCMLf, contributing significantly to its mission of improving outcomes for patients with CML worldwide.
He serves as a member of the iCMLf Scientific Advisory Committee, helping guide the Foundation’s scientific and educational initiatives. In addition, he has led the module of Pediatric CML within the iCMLf Knowledge Centre and the development of pediatric CML case studies, an educational initiative designed to bring together international experts and clinicians from low- and middle-income countries (LMICs) to discuss challenging real-world pediatric CML cases.